AOD-9604

What is AOD-9604?

AOD-9604 is a small modified fragment of human growth hormone, built from the tail end of the molecule (the 176-191 region). The idea behind it was clever: keep the part of GH that pushes fat metabolism and drop the parts that raise blood sugar and drive general growth. It has been marketed heavily as a fat-loss peptide. The honest headline is that its own human trials did not deliver on that promise.

How AOD-9604 works

AOD-9604 mimics the lipolytic (fat-releasing) tail of growth hormone. In lab and animal work it appeared to stimulate the breakdown of fat and reduce the formation of new fat, and it seemed to do this without the IGF-1 rise, glucose problems, or growth-promoting effects of full GH. Because it does not raise IGF-1, it also does not carry the insulin-resistance concern that comes with growth hormone. That clean mechanism is a big part of why it drew interest.

What the research shows

This is where the story turns. Early mouse studies showed AOD-9604 and GH could reduce body weight and fat, and small early human studies looked promising. But the definitive test, a larger placebo-controlled Phase 2b obesity trial, failed to show clinically meaningful weight loss over placebo at the doses tested, and development as an obesity drug was discontinued around 2007. The safety side was reassuring: no IGF-1 elevation, no glucose problems, no notable adverse signal. So the fair summary is a good safety record paired with weak efficacy for its headline use.

Dosage and how it is used

There is no approved dose. Community protocols commonly reference roughly 300 mcg per day subcutaneously, and it is sometimes described as oral, though oral stability is debated. These figures come from practice, not from a trial that showed the compound actually works for fat loss, so keep that context in mind.

→ How to reconstitute AOD-9604: calculator, units to draw & storage

Side effects and safety

AOD-9604's safety profile in trials was one of its better features. Human studies did not find IGF-1 elevation or glucose disturbance, and adverse events were generally mild. The real caveat is not danger but disappointment: the weight-loss benefit that would justify using it did not hold up against placebo.

• Favorable short-term safety in trials; no IGF-1 rise or glucose problems reported.
• Failed to beat placebo for weight loss in a Phase 2b obesity trial; development was discontinued.
• Not FDA-approved as an obesity drug. Verify current legal status independently.

Frequently asked questions

References

• Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology, 2001.